The estimated Net Worth of V, Llcsv Life Sciences Fund... is at least $1.07 Миллион dollars as of 28 May 2019. V Fund owns over 385,715 units of Bicycle Therapeutics plc stock worth over $1,068,614 and over the last 5 years V sold BCYC stock worth over $0.
V has made over 1 trades of the Bicycle Therapeutics plc stock since 2019, according to the Form 4 filled with the SEC. Most recently V bought 385,715 units of BCYC stock worth $5,400,010 on 28 May 2019.
The largest trade V's ever made was buying 385,715 units of Bicycle Therapeutics plc stock on 28 May 2019 worth over $5,400,010. On average, V trades about 385,715 units every 0 days since 2019. As of 28 May 2019 V still owns at least 39,637 units of Bicycle Therapeutics plc stock.
You can see the complete history of V Fund stock trades at the bottom of the page.
Over the last 5 years, insiders at Bicycle Therapeutics plc have traded over $10,024,476 worth of Bicycle Therapeutics plc stock and bought 3,275,775 units worth $45,860,850 . The most active insiders traders include Plc Gsk, Bros. Advisors Lp667, L.P.B... и Bioventures Ltd Novartis Ag.... On average, Bicycle Therapeutics plc executives and independent directors trade stock every 19 days with the average trade being worth of $1,155,236. The most recent stock trade was executed by Michael Charles Ferguson Ha... on 3 July 2024, trading 246 units of BCYC stock currently worth $4,831.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc executives and other stock owners filed with the SEC include: